Brokers Are Upgrading Their Views On Leap Therapeutics, Inc. (NASDAQ:LPTX) With These New Forecasts

Shareholders in Leap Therapeutics, Inc. (NASDAQ:LPTX) may be thrilled to learn that the analysts have just delivered a major upgrade to their near-term forecasts. Consensus estimates suggest investors could expect greatly increased statutory revenues and earnings per share, with the analysts modelling a real improvement in business performance.

After this upgrade, Leap Therapeutics' five analysts are now forecasting revenues of US$5.9m in 2021. This would be a substantial 422% improvement in sales compared to the last 12 months. The loss per share is anticipated to greatly reduce in the near future, narrowing 50% to US$0.42. Yet before this consensus update, the analysts had been forecasting revenues of US$3.5m and losses of US$0.59 per share in 2021. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates.

See our latest analysis for Leap Therapeutics

The Bottom Line

The highlight for us was that the consensus reduced its estimated losses next year, perhaps suggesting Leap Therapeutics is moving incrementally towards profitability. With a serious upgrade to expectations, it might be time to take another look at Leap Therapeutics.

Analysts are definitely bullish on Leap Therapeutics, but no company is perfect. Indeed, you should know that there are several potential concerns to be aware of, including major dilution from new stock issuance in the past year. You can learn more, and discover the 4 other warning signs we've identified, for free on our platform here.

Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are upgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.